Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

<p>Supplementary Tables</p>

Đã lưu trong:

Chi tiết về thư mục
Tác giả chính:	Koichi Tomoshige (15304682) (author)
Tác giả khác:	William D. Stuart (15304685) (author), Iris M. Fink-Baldauf (15304688) (author), Masaoki Ito (15304691) (author), Tomoshi Tsuchiya (15304694) (author), Takeshi Nagayasu (15304697) (author), Tomoki Yamatsuji (15304700) (author), Morihito Okada (15038418) (author), Takuya Fukazawa (15304703) (author), Minzhe Guo (15304706) (author), Yutaka Maeda (15304709) (author)
Được phát hành:	2025
Những chủ đề:	Cancer Cancer Biology Molecular and Cellular Biology Gene Regulation Promoter/enhancer analysis Lung Cancer Oncogenes & Tumor Suppressors Kras
Các nhãn:	Thêm thẻ Không có thẻ, Là người đầu tiên thẻ bản ghi này!

Những quyển sách tương tự

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
Bằng: Craig M. Goodwin (14955973)
Được phát hành: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Bằng: Nicholas T. Younger (14956251)
Được phát hành: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Bằng: Nicholas T. Younger (14956251)
Được phát hành: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Bằng: Nicholas T. Younger (14956251)
Được phát hành: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
Bằng: Nicholas T. Younger (14956251)
Được phát hành: (2025)

Supplementary Table 1 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Bằng: Dhruv Chachad (14954640)
Được phát hành: (2025)

Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Bằng: Dhruv Chachad (14954640)
Được phát hành: (2025)

Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Bằng: Dhruv Chachad (14954640)
Được phát hành: (2025)

Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Bằng: Dhruv Chachad (14954640)
Được phát hành: (2025)

Supplementary Table 5 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
Bằng: Dhruv Chachad (14954640)
Được phát hành: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Bằng: Man Xu (14963249)
Được phát hành: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Bằng: Man Xu (14963249)
Được phát hành: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Bằng: Man Xu (14963249)
Được phát hành: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Bằng: Man Xu (14963249)
Được phát hành: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Bằng: Man Xu (14963249)
Được phát hành: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Bằng: Man Xu (14963249)
Được phát hành: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Bằng: Man Xu (14963249)
Được phát hành: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
Bằng: Man Xu (14963249)
Được phát hành: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
Bằng: Caleb N. Seavey (15056489)
Được phát hành: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
Bằng: Caleb N. Seavey (15056489)
Được phát hành: (2025)

Cannot write session to /tmp/vufind_sessions/sess_8qnfr0358bjbb3temudf9nl7sv